Skip to content

US · XCUR · BIOTECHNOLOGY

Exicure, Inc. (XCUR) intrinsic value and stock valuation

$0.90as of 2026-11-21 · Mkt cap 9.62M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Exicure, Inc. DCF and intrinsic value

InvestorsCraft values XCUR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XCUR’s statements →

Exicure, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94063 exicuretx.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-4.95M
20152025
Free cash flow
-$-8.56M
20152025
Total equity
$3.93M-42.3% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$500K$0.00$28.8M-$-480K
Operating income-$-10.12M-$-12.23M-$-15M-$-1.83M-$-62.55M
Net income-$-4.95M-$-9.7M-$-16.91M-$-2.58M-$-64.1M
EPSd-$-785.71K-$-1.59M-$-2.11M-$-558.44K-$-21.73M
Operating cash flow-$-8.55M-$-2.91M-$-10.36M-$-35.66M-$-34.82M
Capital expenditure-$0.00$0.00$0.00-$-10K-$-970K
Free cash flow-$-8.56M-$-2.91M-$-10.36M-$-35.67M-$-35.79M
Total assets$14M$15.1M$11.6M$23.3M$64.9M
Total debt$180K$5.93M$6.67M$7.31M$14.7M
Net debt-$-3.57M-$-6.57M$5.85M-$-1.27M-$-19.91M
Total equity$3.93M$6.77M$3.03M$14.9M$11.2M
Cash and short-term investments$3.75M$12.5M$820K$8.58M$39.1M
Income statement
20252024202320222021
Revenue$0.00$500K$0.00$28.8M-$-480K
Cost of revenue$460K$0.00$1.42M$1.86M$0.00
Gross profit-$-460K$500K-$-1.42M$27M-$-480K
Research and development expenses$3.29M$0.00$1.42M$19.8M$49M
Selling, general and administrative expenses$6.83M$5.45M$12.7M$10.9M$13.1M
Other expenses-$-460K$7.28M-$-500K-$-1.86M$0.00
Operating expenses$9.66M$12.7M$13.6M$28.8M$62.1M
Cost and expenses$10.1M$12.7M$15M$30.7M$62.1M
Interest income$30K$10K$30K$10K$140K
Interest expense$0.00$20K$0.00$590K$1.69M
Depreciation and amortization$460K$820K$1.38M$1.86M$1.78M
Ebitda-$-5.12M-$-8.85M-$-15.54M$80K-$-60.63M
Operating income-$-10.12M-$-12.23M-$-15M-$-1.83M-$-62.55M
Total other income/expenses, net$4.54M$2.54M-$-1.92M-$-540K-$-1.55M
Income before tax-$-5.58M-$-9.69M-$-16.91M-$-2.37M-$-64.1M
Income tax expense-$-630K$10K$0.00$210K$0.00
Net income-$-4.95M-$-9.7M-$-16.91M-$-2.58M-$-64.1M
Weighted average shares outstanding$6.3M$6.1M$8.01M$4.62M$2.95M
Weighted average diluted shares outstanding$6.3M$6.1M$8.01M$4.62M$2.95M
Balance sheet
20252024202320222021
Cash and short-term investments$3.75M$12.5M$820K$8.58M$39.1M
Net receivables$60K$520K$250K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$4.62M$13.7M$2.02M$10.1M$43.7M
Property, plant and equipment, net$310K$30K$6.57M$9.79M$11.9M
Goodwill and intangible assets$8.18M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$1.2M$1.2M$0.00
Total non-current assets$9.42M$1.38M$9.56M$13.3M$21.2M
Total assets$14M$15.1M$11.6M$23.3M$64.9M
Accounts payable$1.69M$1.03M$1.63M$360K$3.41M
Short-term debt$180K$720K$630K$540K$7.33M
Deferred revenue$0.00$0.00$0.00$0.00$17.3M
Total current liabilities$3.89M$3.07M$2.51M$1.64M$34.1M
Long-term debt$0.00$5.21M$6.04M$6.77M$7.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$11.5M
Total non-current liabilities$6.23M$5.21M$6.04M$6.77M$19.6M
Capital lease obligations$0.00$5.93M$6.67M$6.77M$7.86M
Total liabilities$10.1M$8.28M$8.55M$8.41M$53.6M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-204.21M-$-199.26M-$-189.56M-$-172.65M-$-170.07M
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00$0.00-$0.00
Total equity$3.93M$6.77M$3.03M$14.9M$11.2M
Total investments$0.00$0.00$1.2M$1.2M$4.5M
Total debt$180K$5.93M$6.67M$7.31M$14.7M
Net debt-$-3.57M-$-6.57M$5.85M-$-1.27M-$-19.91M
Cash flow statement
20252024202320222021
Net income-$-4.95M-$-9.7M-$-16.91M-$-2.58M-$-64.1M
Depreciation and amortization$460K$820K$1.38M$1.86M$1.78M
Stock-based compensation$0.00$20K$1.35M$1.37M$2.94M
Change in working capital$1.14M$630K$910K-$-36.81M$24.1M
Accounts receivable$1.34M-$-510K$0.00$0.00$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$180K-$-190K$1.27M-$-3.05M$1.58M
Net cash provided by operating activities-$-8.55M-$-2.91M-$-10.36M-$-35.66M-$-34.82M
Investments in property, plant and equipment-$0.00$0.00$0.00-$-10K-$-970K
Acquisitions, net-$-1.81M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.81M$0.00-$-1.08M$4.7M$43.1M
Common stock issued$1.6M$12.4M$5.44M$5.04M$11.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.6M$13.4M$3.67M-$-3.1M$1.12M
Net change in cash-$-8.76M$10.5M-$-7.76M-$-34.07M$9.38M
Cash at end of period$3.75M$12.5M$2.02M$9.78M$43.8M
Operating cash flow-$-8.55M-$-2.91M-$-10.36M-$-35.66M-$-34.82M
Capital expenditure-$0.00$0.00$0.00-$-10K-$-970K
Free cash flow-$-8.56M-$-2.91M-$-10.36M-$-35.67M-$-35.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Exicure, Inc.

        Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.

        CEO
        Jungsoo Kim
        Employees
        2
        Beta
        3.60

        Explore

        Frequently asked questions

        What is the intrinsic value of Exicure, Inc. (XCUR)?

        InvestorsCraft does not currently publish an intrinsic value for XCUR. How the IC value is calculated.

        Is XCUR undervalued?

        InvestorsCraft does not publish an undervaluation signal for XCUR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.